{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:02:12Z","timestamp":1791846132091,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euf.2025.12.010","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:13:14Z","timestamp":1766128394000},"page":"486-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-669X","authenticated-orcid":false,"given":"Keiichiro","family":"Miyajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman S.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Alfarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Oliveira","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.12.010_b0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette-Gu\u00e9rin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.010_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","article-title":"Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study","volume":"39","author":"Grossmann","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.12.010_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.juro.2006.09.038","article-title":"Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma","volume":"177","author":"Shariat","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.euf.2024.11.003","article-title":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis of matched cohort studies","volume":"11","author":"Matsukawa","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.12.010_b0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2013.09.050","article-title":"Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/MOU.0000000000001220","article-title":"Bladder sparing options for muscle-invasive bladder cancer","volume":"34","author":"Laukhtina","year":"2024","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2025.02.051","article-title":"Survival outcomes and temporal trends of non-surgical management vs radical cystectomy in non-organ-confined urothelial bladder cancer","volume":"200","author":"Longoni","year":"2025","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.010_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7306198","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JU.0000000000001696","article-title":"Complications and outcomes of salvage cystectomy after trimodality therapy","volume":"206","author":"Pieretti","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0080","doi-asserted-by":"crossref","unstructured":"Pyrgidis N, Schulz GB, Scilipoti P, et al. The role of salvage cystectomy after prior trimodality therapy: a multinational match-paired analysis. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.04.028.","DOI":"10.1016\/j.euf.2025.04.028"},{"key":"10.1016\/j.euf.2025.12.010_b0085","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00345-020-03436-0","article-title":"Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"39","author":"Schuettfort","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/JU.0000000000000512","article-title":"Decision regret related to urinary diversion choice among patients treated with cystectomy","volume":"203","author":"Check","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2015.12.079","article-title":"Recent trends in postcystectomy health-related quality of life (QoL) favors neobladder diversion: systematic review of the literature","volume":"93","author":"Ghosh","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.010_b0105","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s11136-018-1902-8","article-title":"Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis","volume":"27","author":"Shi","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euf.2025.12.010_b0110","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.euf.2025.12.010_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.010_b0120","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.010_b0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.euf.2025.12.010_b0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.12.010_b0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urology.2018.07.058","article-title":"Long-term outcomes and patterns of failure following trimodality treatment with bladder preservation for invasive bladder cancer","volume":"124","author":"B\u00fcchser","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.010_b0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajur.2021.06.006","article-title":"A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasivebladder cancer","volume":"9","author":"Dracham","year":"2022","journal-title":"Asian J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0155","first-page":"1","article-title":"Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"27","author":"Elsayed","year":"2023","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.euf.2025.12.010_b0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42378","article-title":"Analysis of MRE11 and mortality among adults with muscle-invasive bladder cancer managed with trimodality therapy","volume":"5","author":"Magliocco","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2025.12.010_b0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5489\/cuaj.6459","article-title":"Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer","volume":"14","author":"Ajib","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euf.2025.12.010_b0170","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jgo.2022.05.014","article-title":"Bladder preservation in older adults with muscle-invasive bladder cancer: a retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule","volume":"13","author":"Alati","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0175","doi-asserted-by":"crossref","first-page":"194.e15","DOI":"10.1016\/j.urolonc.2021.11.002","article-title":"Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer","volume":"40","author":"Almarzouq","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0180","doi-asserted-by":"crossref","first-page":"174","DOI":"10.31086\/tjgeri.2021.213","article-title":"Bladder preservation with image-guided radiotherapy for elderly patients with muscle-invasive bladder cancer: a single institution experience","volume":"24","author":"Aynaci","year":"2021","journal-title":"Turk Geriatri Dergisi"},{"key":"10.1016\/j.euf.2025.12.010_b0185","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/cam4.3835","article-title":"Disparities in male versus female oncologic outcomes following bladder preservation: a population-based cohort study","volume":"10","author":"Ballas","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2025.12.010_b0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/cancers14235766","article-title":"Differences in cancer-specific mortality after trimodal therapy for T2N0M0 bladder cancer according to histological subtype","volume":"14","author":"Barletta","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.12.010_b0195","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4143\/crt.2024.015","article-title":"Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: post hoc analysis of two prospective studies","volume":"56","author":"Cho","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euf.2025.12.010_b0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euros.2022.02.010","article-title":"A multicenter retrospective cohort series of muscle-invasive bladder cancer patients treated with definitive concurrent chemoradiotherapy in daily practice","volume":"39","author":"de Ruiter","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.12.010_b0205","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/0284186X.2021.1915498","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer","volume":"60","author":"Fabiano","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0210","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1002\/cam4.3478","article-title":"Trimodal therapy in T2-4aN0M0 bladder cancer\u2014how to select the best candidate?","volume":"9","author":"Gofrit","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2025.12.010_b0215","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2015.109","article-title":"Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder","volume":"112","author":"Hafeez","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2025.12.010_b0220","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/jjco\/hyr064","article-title":"Primary cT2 bladder cancer: a good candidate for radiotherapy combined with cisplatin for bladder preservation","volume":"41","author":"Hara","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2021.11.011","article-title":"Role of serum lymphocyte-derived biomarkers in nonmetastatic muscle-invasive bladder cancer patients treated with trimodal therapy","volume":"36","author":"Kool","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.12.010_b0230","doi-asserted-by":"crossref","first-page":"274.e1","DOI":"10.1016\/j.urolonc.2022.01.010","article-title":"Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer","volume":"40","author":"Kotha","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0235","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5489\/cuaj.4008","article-title":"Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer","volume":"11","author":"McPherson","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euf.2025.12.010_b0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2018.12.028","article-title":"MicroRNA biomarkers for patients with muscle-invasive bladder cancer undergoing selective bladder-sparing trimodality treatment","volume":"104","author":"Meng","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.12.010_b0245","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/cancers15061886","article-title":"Elevated baseline neutrophil count correlates with worse outcomes in patients with muscle-invasive bladder cancer treated with chemoradiation","volume":"15","author":"Meunier","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2025.12.010_b0250","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.15983","article-title":"Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients","volume":"132","author":"Mignot","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.010_b0255","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jjco\/hyz211","article-title":"The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer","volume":"50","author":"Miyata","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0260","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000477912","article-title":"The efficacy of trimodal chemoradiotherapy with cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer","volume":"99","author":"Nagao","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2025.12.010_b0265","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3892\/mco.2014.264","article-title":"Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation","volume":"2","author":"Shilkrut","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0270","first-page":"2605","article-title":"Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy","volume":"33","author":"Wu","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euf.2025.12.010_b0275","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.2147\/CMAR.S283954","article-title":"The significance of neutrophil-to-lymphocyte ratio and combined chemoradiotherapy in patients undergoing bladder preservation therapy for muscle-invasive bladder cancer","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.euf.2025.12.010_b0280","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1464-410X.2007.07408.x","article-title":"C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy","volume":"101","author":"Yoshida","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.010_b0285","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.urolonc.2009.01.031","article-title":"Updated results of bladder-sparing trimodality approach for invasive bladder cancer","volume":"28","author":"Zapatero","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0290","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0295","doi-asserted-by":"crossref","first-page":"151.e17","DOI":"10.1016\/j.urolonc.2016.11.003","article-title":"The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: implications for follow-up schemes","volume":"35","author":"Moschini","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.010_b0300","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.010_b0305","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.urology.2006.03.033","article-title":"Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy","volume":"68","author":"Shariat","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.010_b0310","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1097\/01.ju.0000154696.48217.75","article-title":"Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder","volume":"173","author":"Shariat","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0315","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00345-018-2450-0","article-title":"Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2025.12.010_b0320","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.euf.2025.12.010_b0325","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS720","article-title":"Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euf.2025.12.010_b0330","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","article-title":"INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: safety update on first 73 patients","volume":"39","author":"Singh","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:30:29Z","timestamp":1785529829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405456925003645"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}